Reply: Can We Really Skip the Biopsy in Diagnosing Symptomatic Children With Celiac Disease by Husby, Steffen et al.
Co
LETTERS TO THE EDITORCan We Really Skip the Biopsy in
Diagnosing Symptomatic Children
With Celiac DiseaseT o the Editor: In the March 2013 issue of the Journal ofPediatric Gastroenterology and Nutrition, Klapp et al (1)
reviewed 150 symptomatic children with celiac disease, finding that
the positive predictive value of applying these new criteria was
97.4%, and concluding that the diagnosis of celiac disease can be
accurately made in a selected population without the requirement of
a duodenal biopsy, following the new European Society for
Pediatric Gastroenetrology, Hepatology, and Nutrition guidelines
(2). We performed a multicenter retrospective chart review (3)
aimed at determining how many patients would avoid the biopsy
and at verifying potential drawbacks of eliminating endoscopy.
A total of 279 symptomatic patients (mean age 8.6 years)
from 4 US centers had data available for both tissue transglutami-
nase-immunoglobulin A (tTG) and endomysium antibodies-immu-
noglobulin A. One hundred twenty-six patients (45%) had tTG
>10 normal and positive EMA. Of these 126 patients, 115 (91%)
underwent endoscopy with biopsies. Pathology reports showed all
of them to have celiac disease (74% Marsh 3); however, 10% of
them had unexpected additional diagnoses: chronic gastritis (2),
reflux esophagitis (5), esophagitis (2), eosinophilic esophagitis (1),
and Helicobacter pylori (1). Sixteen additional asymptomatic
patients in our series also had tTG >10 normal and positive
endomysium antibodies-immunoglobulin A. Of them, only 1 had an
unexpected diagnosis (H pylori).
Thus, although we also found that a large portion of our
patients would have been properly diagnosed as having celiac
disease without a biopsy, by avoiding the diagnostic procedure,
additional, unexpected diagnoses would have been missed in>10%
of such symptomatic patients. We urge careful follow-up of symp-
tomatic patients after they are diagnosed without a biopsy to avoid
overlooking associated conditions.
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Authors’ Responsez
T o the Editor: Guandalini and Newland express concern thatother diagnoses of the upper gastrointestinal tract will be
missed if the diagnosis of celiac disease (CD) is made without
performing an upper endoscopy. We thank the authors for pointing
out this issue and the journal for affording us the chance to respond.pyright 2013 by ESPGHAN and NASPGHAN. Un
The authors report the results of their retrospective chart
review with endoscopic findings in 115 children with anti-TG2
e24antibody concentrations >10 times the upper limit of normal.
According to the new European Society for Pediatric Gastroenter-
ology, Hepatology, and Nutrition (ESPGHAN) guidelines on the
diagnosis of CD, these patients would qualify for the option to omit
the biopsies under the following conditions in addition to the high
TG2 antibody concentrations: symptoms suggestive of CD, positive
anti-endomysial antibodies in a second blood sample, HLA-DQ2 or
-DQ8 positivity, and informed consent after discussion with a
pediatric gastroenterologist (1). In 11 of 115 patients, abnormal
findings were reported; however, we would consider some of them
less relevant or part of the celiac pathology. For example, Helico-
bacter pylori infection does not need to be treated in the absence of
erosions and ulcerations (2). Chronic superficial or lymphocytic
gastritis are common findings in children with untreated CD (3,4)
and should resolve with a gluten-free diet. The remaining patients
had different types of esophagitis, one of them with eosinophilic
infiltrations. No information is provided as to whether the diagnosis
of esophagitis was based on macroscopic findings with mucosal
breaks (erosions, ulcerations) or histology only.
Untreated CD causes dysmotility with delayed gastric emp-
tying because of reduced secretion of gastrointestinal hormones in
the presence of enteropathy. This may predispose to gastroesopha-
geal reflux and esophagitis, but again, dysmotility will resolve after
normalization of the small bowel mucosa with a gluten-free diet. In
addition, it is unclear how many unselected control children would
show any esophageal pathology. The Kalixanda study reports
findings in 1000 population-based adults who underwent upper
endoscopy with multiple biopsies. Even in the absence of any
symptoms, 9.5% were found to have erosive esophagitis. This
proportion reached 20% to 36% in individuals complaining of
occasional to daily symptoms (5). In the same study, definite or
probable eosinophilic esophagits (EoE) was identified in 1.1%, and
eosinophilic infiltrations were related to reflux esophagitis (6). It
has been suggested that EoE is more frequent than expected in
patients with CD; however, a recent meta-analysis on incidence and
prevalence of EoE in children reported a prevalence ranging from
1.1% to 5.1% in CD compared with 2.1% to 4.9% in children who
underwent endoscopy for abdominal pain (7).
The data point to the dilemma that a concurrent disease may be
responsible for the symptoms leading to medical attention, and CD
essentially may be asymptomatic. Symptomatology and clinical
judgment are important elements of the ESPGHAN guidelines. In
cases in which the type of gastrointestinal symptoms (mainly abdomi-
nal pain) indicates the possibility of additional pathology, it is at the
discretion of the managing physician to perform an endoscopy
already at the beginning of the clinical workup. Although CD cannot
be diagnosed after starting the diet, an endoscopical search for
additional pathology can be performed at any later time in those
children whose symptoms do not respond to a gluten-free diet. This
would still spare a majority from the invasive procedure.
In conclusion, we believe that the findings observed by
Guandalini and Newland do not justify changing the ESPGHAN
guidelines and the option to omit duodenal biopsies. At the same
time, we strongly support their recommendation to follow-up on
these children receiving a gluten-free diet and evaluate those in
whom symptoms do not resolve.
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Antitumor Necrosis Factor, Infliximab,
and Adalimumab: Use With Caution in
JPGN  Volume 57, Number 4, October 2013Eosinophilic Bowel DiseaseT o the Editor: We read the article by Turner et al (1) with greatinterest and concern because it proposes that ‘‘infliximab and
adalimumab may be effective in refractory idiopathic eosinophilic
enterocolitis’’ (EEC). Our concerns lie in the lack of diagnostic
clarity, uncertainty of clinical efficacy of the treatments, the
suggested chronic use of medications with significant potential
adverse effects, and uncertain therapeutic rationale. Histological
features defining eosinophilic gastrointestinal disease beyond the
esophagus remain difficult to define, and parameters defining EEC
are even less clear. The authors quote 3 review references that provide
no diagnostic clarity regarding EEC (2–4). Because images of
histological slides were not included, the histological parameters
used to define EEC in the presented patients remain unclear.
We are uncertain whether the pain experienced can be clearly
ascribed to the duodenal eosinophilia or vice versa because it relates
to the 5 responsive patients. Three patients showed a decrease in
duodenal eosinophil numbers, 1 remained the same, and 1 was not
reassessed. Although 3 patients experienced reduction in pain and a
decrease in eosinophilia, the cause and effect are difficult to
ascertain because there is a significant placebo effect associated
with abdominal pain. Systemic and topical steroids, medications
known to decrease mucosal eosinophilia, did not reduce symptoms
in 3 of 5 of these patients. A further confounder is the long time
intervals that occurred in some of the patients between initiating the
biological treatments and obtaining the mucosal findings; this raises
the question of how the mucosa appeared at the beginning of
biological treatment.
The long treatment duration and lack of documented toxicitypyright 2013 by ESPGHAN and NASPGHAN. Un
monitoring are concerning because they appear to support the use of
these medications at ‘‘higher doses than practiced for IBD’’ for up
www.jpgn.orgto 6 years without significant risk (5). Although there is a small
body of literature suggesting that TNF-a is a therapeutic target for
eosinophilic esophagitis, evidence supporting its role in other
eosinophilic gastrointestinal diseases is lacking (6).
The authors suggest that additional studies are warranted;
however, we propose that until more supportive evidence becomes
available, these medications be used with extreme caution for well-
defined time periods and accompanied by close monitoring for
adverse effects.
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Letters to the EditorAuthors’ ResponseT o the Editor: We thank Furuta et al for the opportunity toclarify our standpoint regarding the possible effectiveness of
antitumor necrosis factor (anti-TNF) in eosinophilic enterocolitis
(EEC).
Certainly, case reports should not be used to change clinical
practice. They are, however, a rich source of hypotheses to be
tested in further studies of more robust design. Our reported
children had poor quality of life because of severe ongoing
symptoms despite treatment attempts with all of the standard
interventions. In these extreme cases, one often considers uncon-
ventional treatments, despite the lack of level I evidence. Specifi-
cally in EEC, which is extremely rare, its pathophysiology is totally
obscure, and all suggested treatments to date have been based on
case series only.
Despite the inherent biases and limitations of our case series,
which we tried to minimize, there is more to suggest that treatment
with anti-TNF was beneficial. Response to the drug was rapid and
obvious in the responsive cases, in a similar manner to what we see
in IBD. When available, repeated biopsies did show marked
improvement, and the loss of response to infliximab was in decreas-authorized reproduction of this article is prohibited.
ing intervals from the previous infusions, lending support to a true
biological effect of the drug. All of the cases were previously
e25
Corefractory to multiple aggressive therapies and there is no reason to
believe that suddenly a placebo effect will be so striking only with
anti-TNF.
We do not suggest that anti-TNF should be routinely used in
EEC. We fully agree with Furuta et al that a trial of anti-TNF
treatment in EEC should only be considered at this time in severe
and resistant cases, accompanied by monitoring for adverse effects
Letters to the Editorpyright 2013 by ESPGHAN and NASPGHAN. Un
(including repeated biopsies) to ensure that the drug is indeed
e26effective. It is also reasonable to plan exit strategies in the respon-
sive cases. Indeed, the literature is eagerly awaiting level I evidence
for effective therapies and ‘‘diagnostic clarity’’ of EEN, but until
then, we must still treat our patients, making use of the best-
available evidence.
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